M
Michael B. Sporn
Researcher at Dartmouth College
Publications - 561
Citations - 96644
Michael B. Sporn is an academic researcher from Dartmouth College. The author has contributed to research in topics: Transforming growth factor & Transforming growth factor beta. The author has an hindex of 157, co-authored 559 publications receiving 94605 citations. Previous affiliations of Michael B. Sporn include Cornell University & Reata Pharmaceuticals.
Papers
More filters
Journal ArticleDOI
NRF2 Protects Mice From Cigarette Smoke-Induced Emphysema
Shyam Biswal,Tirumalai Rangasamy,Thomas E. Sussan,Melinda S. Yates,Michael B. Sporn,Thomas W. Kensler,Rubin M. Tuder +6 more
Proceedings ArticleDOI
NRF2 Is Protective In Neutrophil-Mediated Acute Lung Injury
Bruce A. Davidson,R. Robert Vethanayagam,Melissa J. Grimm,Barbara A. Mullan,Nikolaos G. Almyroudis,Carlos E. Vigil,Timothy S. Blackwell,Wei Han,Michael L. Freeman,Michael B. Sporn,Kiyoshi Itagaki,Carl J. Hauser,Paul R. Knight,Brahm H. Segal +13 more
Journal ArticleDOI
CDDO Increases Translation of CCAAT Enhancer Binding Protein alpha To Induce Granulocytic Differentiation.
Steffen Koschmieder,Francesco D′Alo′,Hanna S. Radomska,Susumu Kobayashi,Elena Levantini,Nanjoo Suh,Michael B. Sporn,Annalisa Di Ruscio,Maria Teresa Voso,Wolfgang E. Berdel,Carsten Müller-Tidow,Hubert Serve,Daniel G. Tenen +12 more
TL;DR: In conclusion, CDDO leads to granulocytic differentiation and translational induction of CEBPA protein, and may provide a novel treatment approach for patients with acute myeloid leukemia.
Journal ArticleDOI
Commentary on Eagle and Foley: “Cytotoxicity in Human Cell Cultures”
TL;DR: From a contemporary perspective in 2016, it is difficult to realize that not very long ago, the prevailing primary screen for testing new anticancer drugs was the lung cancer screening test.